Gemini Therapeutics restructures, cuts 20% of workforce, focuses on GEM103 pivotal trial for GA

Disc Medicine, Inc.

Workforce cut by 20% (11 positions); pre-tax restructuring charge of $1.3M–$1.6M in Q4 2021.
CMO Samuel Barone retains title but no longer oversees regulatory/medical; Avner Ingerman promoted to CDO; Barone eligible for $100K bonus and retention pay.
Chief Scientific Officer (Walter Strapps) and Chief People Officer (Precillia Redmond) roles eliminated by year-end 2021.
Company shifts to development-stage, ceasing research programs to focus on GEM103 pivotal trial in GA planned for early 2022.
CFO Brian Piekos adds Chief Business Officer role; Chair Georges Gemayel becomes Executive Chair.

item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Georges Gemayel

Executive Chair

IRON · Disc Medicine, Inc.

Effective: 2021-10-04
Filed: October 6, 2021, 7:59 PM ET

Finally, Georges Gemayel, Ph.D., will transition to serve as the Executive Chair of the Company’s Board.

Role change

Samuel Barone

Chief Medical Officer

IRON · Disc Medicine, Inc.

Effective: 2021-10-04
Filed: October 6, 2021, 7:59 PM ET

On October 4, 2021, the Company’s Chief Medical Officer, Samuel Barone, M.D., entered into an agreement with the Company (the “Retention Agreement”) to modify his role and responsibilities.

Role change

Brian Piekos

Chief Business Officer

IRON · Disc Medicine, Inc.

Effective: 2021-10-04
Filed: October 6, 2021, 7:59 PM ET

In addition, effective as of October 4, 2021, the Company has appointed Brian Piekos, the Company’s Chief Financial Officer, the additional title of Chief Business Officer, and Mr. Piekos has assumed additional leadership responsibilities for various functions including manufacturing, business development and investor relations.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Georges Gemayel changed role as Executive Chair at Disc Medicine, Inc..

Action: transitioned to serve as
Role: Executive Chair

Exact text from the filing

Finally, Georges Gemayel, Ph.D., will transition to serve as the Executive Chair of the Company’s Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel Barone changed role as Chief Medical Officer at Disc Medicine, Inc..

Action: modified role
Role: Chief Medical Officer

Exact text from the filing

On October 4, 2021, the Company’s Chief Medical Officer, Samuel Barone, M.D., entered into an agreement with the Company (the “Retention Agreement”) to modify his role and responsibilities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Piekos was appointed as Chief Business Officer at Disc Medicine, Inc..

Action: appointed
Role: Chief Business Officer

Exact text from the filing

In addition, effective as of October 4, 2021, the Company has appointed Brian Piekos, the Company’s Chief Financial Officer, the additional title of Chief Business Officer, and Mr. Piekos has assumed additional leadership responsibilities for various functions including manufacturing, business development and investor relations.

View on SEC.gov

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-292589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.